Acute Central Serous Chorioretinopathy Outbreak during the COVID-19 Pandemic: A Pilot Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Participants
2.3. Exclusion Criteria
2.4. Data Collection
2.5. Diagnosis Confirmation
2.6. Protocol for Treatment and Follow-Up
2.7. Comparison of Periods
2.8. Statistical Analysis
2.9. Sample Size
3. Results
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Spaide, R.F.; Campeas, L.; Haas, A.; Yannuzzi, L.A.; Fisher, Y.L.; Guyer, D.R.; Slakter, J.S.; Sorenson, J.A.; Orlock, D.A. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996, 103, 2070–2080. [Google Scholar] [CrossRef] [PubMed]
- Kitzmann, A.S.; Pulido, J.S.; Diehl, N.N.; Hodge, D.O.; Burke, J.P. The Incidence of Central Serous Chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 2008, 115, 169–173. [Google Scholar] [CrossRef] [PubMed]
- Yannuzzi, L.A. Type-a behavior and central serous chorioretinopathy. Retina 1987, 7, 111–131. [Google Scholar] [CrossRef] [PubMed]
- Abouammoh, M.A. Advances in the treatment of central serous chorioretinopathy. Saudi J. Ophthalmol. 2015, 29, 278–286. [Google Scholar] [CrossRef] [PubMed]
- Ruiz-Moreno, J.M.; Lugo, F.L.; Armadá, F.; Silva, R.; Montero, J.A.; Arevalo, J.F.; Arias, L.; Gómez-Ulla, F. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol. 2010, 88, 371–376. [Google Scholar] [CrossRef]
- Bae, S.H.; Heo, J.; Kim, C.; Kim, T.W.; Shin, J.Y.; Song, S.J.; Park, T.K.; Moon, S.W.; Chung, H. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: One-year results of a randomized trial. Ophthalmology 2014, 121, 558–565. [Google Scholar] [CrossRef]
- Nicoló, M.; Eandi, C.M.; Alovisi, C.; Grignolo, F.M.; Traverso, C.E.; Musetti, D.; Piccolino, F.C. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am. J. Ophthalmol. 2014, 157, 1033–1037.E2. [Google Scholar] [CrossRef]
- Bousquet, E.; Beydoun, T.; Zhao, M.; Hassan, L.; Offret, O.; Behar-Cohen, F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: A pilot study. Retina 2013, 33, 2096–2102. [Google Scholar] [CrossRef]
- Zhao, M.; Célérier, I.; Bousquet, E.; Jeanny, J.-C.; Jonet, L.; Savoldelli, M.; Offret, O.; Curan, A.; Farman, N.; Jaisser, F.; et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J. Clin. Investig. 2012, 122, 2672–2679. [Google Scholar] [CrossRef]
- Chin, E.; Almeida, D.; Roybal, C.N.; Niles, P.; Gehrs, K.; Sohn, E.; Boldt, C.; Russell, S.; Folk, J. Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy. Clin. Ophthalmol. 2015, 9, 1449–1456. [Google Scholar] [CrossRef]
- Forooghian, F.; Meleth, A.D.; Cukras, C.; Chew, E.Y.; Wong, W.T.; Meyerle, C.B. Finasteride for chronic central serous chorioretinopathy. Retina 2011, 31, 766–771. [Google Scholar] [CrossRef] [PubMed]
- Bousquet, E.; Beydoun, T.; Rothschild, P.-R.; Bergin, C.; Zhao, M.; Batista, R.; Brandely, M.-L.; Couraud, B.; Farman, N.; Gaudric, A.; et al. Spironolactone for nonresolving central serous chorioretinopathy a randomized controlled crossover study. Retina 2015, 35, 2505–2515. [Google Scholar] [CrossRef] [PubMed]
- Steinle, N.C.; Gupta, N.; Yuan, A.; Singh, R.P. Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br. J. Ophthalmol. 2012, 96, 10–13. [Google Scholar] [CrossRef]
- Lotery, A.; Sivaprasad, P.S.; O’Connell, A.; Harris, R.A.; Culliford, L.; Ellis, L.; Cree, A.; Madhusudhan, S.; Behar-Cohen, P.F.; Chakravarthy, U.; et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): A randomised, double-blind, placebo-controlled trial. Lancet 2020, 395, 294–303. [Google Scholar] [CrossRef] [PubMed]
- Gramajo, A.L.; Marquez, G.E.; Torres, V.E.; Juárez, C.P.; Rosenstein, R.E.; Luna, J.D. Therapeutic benefit of melatonin in refractory central serous chorioretinopathy. Eye 2015, 29, 1036–1045. [Google Scholar] [CrossRef] [PubMed]
- Lim, J.W.; Kim, M.U.; Shin, M.C. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 2010, 30, 1465–1471. [Google Scholar] [CrossRef] [PubMed]
- Chung, Y.R.; Seo, E.J.; Lew, H.M.; Lee, K.H. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: Meta-analysis and review. Eye 2013, 27, 1339–1346. [Google Scholar] [CrossRef] [PubMed]
- Chan, W.M.; Lai, T.Y.Y.; Liu, D.T.L.; Lam, D.S.C. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am. J. Ophthalmol. 2007, 143, 977–983.E1. [Google Scholar] [CrossRef]
- Chrapek, O.; Špačková, K.; Řehák, J. Treatment of Central Serous Chorioretinopathy with Beta Blockers. Cesk Slov. Oftalmol. 2002, 58, 382–386. Available online: https://europepmc.org/article/MED/12629852 (accessed on 18 December 2023). [CrossRef]
- Chrapek, O.; Jirkova, B.; Kandrnal, V.; Rehak, J.; Sin, M. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2015, 159, 120–123. [Google Scholar] [CrossRef]
- Min Kim, H.; Ahn, J.; Wan Kim, T. Psychological Factors Associated with Central Serous Chorioretinopathy. J. Psychol. Psychother. 2016, 6, 250. [Google Scholar] [CrossRef]
- Bazzazi, N.; Ahmadpanah, M.; Akbarzadeh, S.; Rabiei, M.A.S.; Holsboer-Trachsler, E.; Brand, S. In patients suffering from idiopathic central serous chorioretinopathy, anxiety scores are higher than in healthy controls, but do not vary according to sex or repeated central serous chorioretinopathy. Neuropsychiatr. Dis. Treat. 2015, 11, 1131–1136. [Google Scholar] [CrossRef] [PubMed]
- Rosen, B.; Waitzberg, R.; Israeli, A. Israel’s rapid rollout of vaccinations for COVID-19. Isr. J. Health Policy Res. 2021, 10, 6. [Google Scholar] [CrossRef] [PubMed]
- Cumulative Graph of COVID-19 Cases in Israel—Logarithmic Scale. Available online: https://www.science.co.il/medical/covid-19/Statistics-log.php (accessed on 24 June 2023).
- WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19—11 March 2020. Available online: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed on 22 May 2020).
- WHO Coronavirus Disease (COVID-19) Dashboard|WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 14 September 2020).
- Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020, 180, 934–943. [Google Scholar] [CrossRef] [PubMed]
- Bikdeli, B.; Madhavan, M.V.; Jimenez, D.; Chuich, T.; Dreyfus, I.; Driggin, E.; Der Nigoghossian, C.; Ageno, W.; Madjid, M.; Guo, Y.; et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J. Am. Coll. Cardiol. 2020, 75, 2950–2973. [Google Scholar] [CrossRef] [PubMed]
- Klok, F.A.; Kruip, M.J.H.A.; van der Meer, N.J.M.; Arbous, M.S.; Gommers, D.A.M.P.J.; Kant, K.M.; Kaptein, F.H.J.; van Paassen, J.; Stals, M.A.M.; Huisman, M.V.; et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020, 191, 145–147. [Google Scholar] [CrossRef] [PubMed]
- Khavandi, S.; Tabibzadeh, E.; Naderan, M.; Shoar, S. Corona virus disease-19 (COVID-19) presenting as conjunctivitis: Atypically high-risk during a pandemic. Contact Lens Anterior Eye 2020, 43, 211–212. [Google Scholar] [CrossRef] [PubMed]
- Landecho, M.F.; Yuste, J.R.; Gándara, E.; Sunsundegui, P.; Quiroga, J.; Alcaide, A.B.; García-Layana, A. COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease? J. Intern. Med. 2020, 289, 116–120. [Google Scholar] [CrossRef]
- Marinho, P.M.; Marcos, A.A.A.; Romano, A.C.; Nascimento, H.; Belfort, R. Retinal findings in patients with COVID-19. Lancet 2020, 395, 1610. [Google Scholar] [CrossRef]
- Virgo, J.; Mohamed, M. Paracentral acute middle maculopathy and acute macular neuroretinopathy following SARS-CoV-2 infection. Eye 2020, 34, 2352–2353. [Google Scholar] [CrossRef]
- Insausti-García, A.; Reche-Sainz, J.A.; Ruiz-Arranz, C.; López Vázquez, Á.; Ferro-Osuna, M. Papillophlebitis in a COVID-19 patient: Inflammation and hypercoagulable state. Eur. J. Ophthalmol. 2020, 32, NP168–NP172. [Google Scholar] [CrossRef] [PubMed]
- Yahalomi, T.; Pikkel, J.; Arnon, R.; Pessach, Y. Central retinal vein occlusion in a young healthy COVID-19 patient: A case report. Am. J. Ophthalmol. Case Rep. 2020, 20, 100992. [Google Scholar] [CrossRef] [PubMed]
- Our Ongoing List of How Countries Are Reopening, and Which Ones Remain under Lockdown|Business Insider. Available online: https://www.businessinsider.com/countries-on-lockdown-coronavirus-italy-2020-3 (accessed on 24 April 2021).
- “Loss of Working Hours to Equal 195m Full-Time Jobs, UN Agency Warns.” Financial Times. Available online: https://www.ft.com/content/d78b8183-ade7-49c2-a8b5-c40fb031b801 (accessed on 24 April 2021).
- Kar, S.K.; Menon, V.; Arafat, S.M.Y.; Rai, S.; Kaliamoorthy, C.; Akter, H.; Shukla, S.; Sharma, N.; Roy, D.; Sridhar, V.K. Impact of COVID-19 pandemic related lockdown on Suicide: Analysis of newspaper reports during pre-lockdown and lockdown period in Bangladesh and India. Asian J. Psychiatr. 2021, 60, 102649. [Google Scholar] [CrossRef] [PubMed]
- Allen, S.F.; Stevenson, J.; Lazuras, L.; Akram, U. The role of the COVID-19 pandemic in altered psychological well-being, mental health and sleep: An online cross-sectional study. Psychol. Health Med. 2022, 27, 343–351. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Zhou, Y.; Qian, W.; Zhou, Y.; Han, R.; Liu, Z. Maternal insomnia during the COVID-19 pandemic: Associations with depression and anxiety. Soc. Psychiatry Psychiatr. Epidemiol. 2021, 56, 1477–1485. [Google Scholar] [CrossRef] [PubMed]
- Kohls, E.; Baldofski, S.; Moeller, R.; Klemm, S.-L.; Rummel-Kluge, C. Mental Health, Social and Emotional Well-Being, and Perceived Burdens of University Students during COVID-19 Pandemic Lockdown in Germany. Front. Psychiatry 2021, 12, 643957. [Google Scholar] [CrossRef] [PubMed]
- Webb, L.; Figueroa, N.; Tenewitz, J.; Sharma, A.; Kumar, G.; Shaikh, S. Effects of Stress from COVID-19 on Chronic Central Serous Retinopathy. Investig. Ophthalmol. Vis. Sci. 2021, 62, 2187. [Google Scholar]
- Amiri-Dashatan, N.; Koushki, M.; Parsamanesh, N.; Chiti, H. Serum cortisol concentration and COVID-19 severity: A systematic review and meta-analysis. J. Investig. Med. 2022, 70, 766–772. [Google Scholar] [CrossRef]
- Popescu, M.; Terzea, D.C.; Carsote, M.; Ghenea, A.E.; Costache, A.; Popescu, I.A.S.; Biciuşcă, V.; Busuioc, C.J.; Ghemigian, A.M. COVID-19 infection: From stress-related cortisol levels to adrenal glands infarction. Rom. J. Morphol. Embryol. 2022, 63, 39. [Google Scholar] [CrossRef]
- Zakir, S.M.; Shukla, M.; Simi, Z.U.R.; Ahmad, J.; Sajid, M. Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy. Indian J. Ophthalmol. 2009, 57, 419. [Google Scholar] [CrossRef]
- Pichi, F.; Aljneibi, S.; Neri, P.; Hay, S.; Dackiw, C.; Ghazi, N.G. Association of Ocular Adverse Events with Inactivated COVID-19 Vaccination in Patients in Abu Dhabi. JAMA Ophthalmol. 2021, 139, 1131–1135. [Google Scholar] [CrossRef] [PubMed]
- Koong, L.R.; Chee, W.K.; Toh, Z.H.; Ng XLe Agrawal, R.; Ho, S.L. Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine. Ocul. Immunol. Inflamm. 2021, 29, 1212–1215. [Google Scholar] [CrossRef] [PubMed]
COVID-19 Pandemic Era (2020) | Non-COVID-19 Pandemic Era (2018, 2019, 2021) | p Value | |
---|---|---|---|
CSCR incidents per population (per 1000 persons) | 17 (0.005) | 18 (0.002) | 0.02 |
Female-Number (%) | 2 (11.7%) | 4 (22.2%) | 0.6 |
Male-Number (%) | 15 (88.2%) | 14 (77.7%) | |
Age-Mean (SD, range) | 42.8 (±3.6, 26–64) | 46.6 (±9.8, 33–70) | 0.2 |
Ocular medical history | |||
Myopia (%) | 5 (29.4%) | 1 (5.5%) | 0.08 |
Previous refractive surgery (%) | 3 (17%) | 1 (5.5%) | 0.33 |
Pseudophakia (%) | 0 (0.0%) | 1 (5.5%) | >0.99 |
Glaucoma (%) | 0 (0.0%) | 1 (5.5%) | >0.99 |
Systemic medical history | |||
Ischemic heart disease (%) | 1 (5.8%) | 2 (11.1%) | >0.99 |
Hypertension (%) | 0 (0.0%) | 2 (11.1%) | 0.22 |
Hyperlipidemia (%) | 0 (0.0%) | 1 (5.5%) | 0.48 |
SLE (%) | 0 (0.0%) | 1 (5.5%) | >0.99 |
BPH (%) | 1 (5.8%) | 0 (0.0%) | 0.48 |
Hyperlipidemia (%) | 0 (0.0%) | 1 (5.5%) | 0.48 |
ADHD (%) | 0 (0.0%) | 1 (5.5%) | 0.48 |
Previous malignancy (%) | 1 (5.8%) | 1 (5.5%) | >0.99 |
DM2 (%) | 1 (5.8%) | 1 (5.5%) | >0.99 |
Active Smoking (%) | 4 (23.5%) | 1 (5.5%) | 0.11 |
COVID-19 Pandemic Era (n = 17) | Non-COVID-19 Pandemic Era (n = 18) | p Value | |
---|---|---|---|
Mean visual acuity at presentation (SD) (LogMar) | 0.43 (±0.36) | 0.20 (±0.13) | p = 0.1 |
Mean time lag between initial presentation and hospital administration (SD) (days) | 33.58 (±10.49) | 22.16 (±20.69) | p = 0.84 |
Mean CMT at presentation (SD) (microns) | 477.70 (±96.17) | 501.62 (±134.05) | p = 0.68 |
Mean Disease remission (SD) (months) | 6.2 (±0.60) | 4.1 (±0.72) | p = 0.08 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yahalomi, T.; Pikkel, Y.S.; Arnon, R.; Kinori, M.; Wood, K.; Pikkel, J. Acute Central Serous Chorioretinopathy Outbreak during the COVID-19 Pandemic: A Pilot Study. Medicina 2024, 60, 122. https://doi.org/10.3390/medicina60010122
Yahalomi T, Pikkel YS, Arnon R, Kinori M, Wood K, Pikkel J. Acute Central Serous Chorioretinopathy Outbreak during the COVID-19 Pandemic: A Pilot Study. Medicina. 2024; 60(1):122. https://doi.org/10.3390/medicina60010122
Chicago/Turabian StyleYahalomi, Tal, Yael Sara Pikkel, Roee Arnon, Michael Kinori, Keren Wood, and Joseph Pikkel. 2024. "Acute Central Serous Chorioretinopathy Outbreak during the COVID-19 Pandemic: A Pilot Study" Medicina 60, no. 1: 122. https://doi.org/10.3390/medicina60010122